1. Introduction {#sec1}
===============

Glioma and meningioma are two common primary brain tumors in adults \[[@B1]\]. Glioma is the most common type representing more than 80% of adult brain tumors \[[@B2]\]. Meningiomas are primarily benign tumors derived from meningothelial cells of the arachnoid membrane \[[@B3]\]. Ionizing radiation and genetic predisposition are well established risk factors for brain tumors \[[@B4]--[@B6]\]. However, little is known about the etiology of brain tumors.

The link between allergy and brain tumorigenesis is attracting much attention but remains largely unknown. Allergy is composed of eczema, hay fever, allergic asthma, and other heterogeneous diseases with complicated mechanisms. Some common allergies are characterized by immediate hypersensitivity reactions and mediated by immunoglobulin E (IgE) generated by B cells as well as T helper cells \[[@B7], [@B8]\]. IgE is a prediagnostic biomarker of allergy \[[@B9], [@B10]\]. Increased serum IgE is a powerful indication for allergic diseases. Both total serum IgE and allergen-specific IgE participate in the allergic response. Specific serum IgE is indicative of allergic sensitization to specific allergens of respiratory tract, food, or other origins. It is hypothesized that a highly active immune system leads to an enhanced tumor immune surveillance through recognizing and killing tumor cells. Whether prediagnostic IgE levels could modify the risk of brain tumors is currently unclear due to inconsistent and inconclusive findings in previous epidemiological studies. We aim to present more precise estimates for roles of prediagnostic total IgE and respiratory allergen-specific IgE levels in brain tumorigenesis by performing a meta-analysis of all published studies.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

A comprehensive literature search was performed in PubMed and Embase databases for eligible studies on the relationship between prediagnostic IgE levels and brain tumors risk. The last search was on June 26, 2014. The following terms were used: immunoglobulin E, IgE, total IgE level, respiratory allergen-specific IgE level, allergic marker, or allergy and brain tumors, brain cancer, glioma, glioblastoma, or meningioma. The references of retrieved studies were also screened for other relevant articles. No language restriction was imposed.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

Studies included into our study have to meet the following inclusion criteria: (1) studies on the relationship between prediagnostic IgE levels and brain tumors risk; (2) studies in case-control or cohort design; and (3) studies presenting odds ratio (ORs), relative risks (RRs), or hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs) for association estimates. Case-only design, case reports, systematic reviews, meta-analysis, animal studies, or studies with duplicated data were all excluded.

2.3. Data Extraction {#sec2.3}
--------------------

Two investigators independently extracted data from each eligible study. The following information was extracted: name of first author, publication year, country of origin, characteristics of subjects, study design, type of brain tumors, number of cases and controls, matching criteria, study period, adjusted factors, RRs or HRs or ORs with 95% CIs for assessment of prediagnostic IgE levels, and type of brain tumors. Disagreements on all terms were resolved by discussion.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The association between prediagnostic IgE levels and brain tumors risk was estimated by calculating the pooled RRs with 95% CIs. Cochran\'s *Q*-statistic test and *I* ^2^ test were performed to evaluate the between-study heterogeneity, and *P* \< 0.05 plus *I* ^2^ \> 50% implicated significant between-study heterogeneity among all included studies \[[@B11], [@B12]\]. The random-effects model by the DerSimonian and Laird method was adopted when the between-study heterogeneity was significant \[[@B13]\]; otherwise, the fixed-effects model by the method of Mantel-Haenszel was used \[[@B14]\]. Stratified analyses by gender and type of brain tumors were also performed. Sensitivity analysis by sequentially omitting single studies one at a time was also carried out to assess the association. Publication bias risk was estimated by Begg\'s funnel plots and Egger\'s test \[[@B15], [@B16]\]. All analyses were performed by use of STATA 12.0 software (StataCorp, College Station, TX, USA). *P* \< 0.05 suggested statistical significance.

3. Results {#sec3}
==========

3.1. Characteristics of Studies Included into the Present Meta-Analysis {#sec3.1}
-----------------------------------------------------------------------

After a comprehensive literature search, we identified 8 independent studies on the association between prediagnostic IgE levels and brain tumors risk with a total of 2,461 cases and 3,934 controls \[[@B17]--[@B23]\]. [Table 1](#tab1){ref-type="table"} summarized the characteristics of all included studies. The studies were published between 2004 and 2013, which were performed primarily in USA and some European countries including Norway. Among the 8 studies, 6 were about the risk of glioma related to prediagnostic IgE levels, while the other 2 were regarding the meningioma risk.

3.2. Association between Total IgE Level and Brain Tumors Risk {#sec3.2}
--------------------------------------------------------------

The pooled RRs showed that elevated level of total IgE was associated with a decreased risk of brain tumors (RR = 0.73; 95% CI 0.61--0.86; *P* \< 0.001) ([Table 2](#tab2){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). Besides, elevated total IgE level was negatively related to the risk of glioma (RR = 0.74; 95% CI 0.62--0.88; *P* = 0.001) ([Table 2](#tab2){ref-type="table"}). Sensitivity analysis did not materially alter the combined results (data not shown).

3.3. Association between Respiratory Allergen-Specific IgE Level and Brain Tumors Risk {#sec3.3}
--------------------------------------------------------------------------------------

No significant association was observed between testing positive for respiratory allergen-specific IgE and brain tumors risk ([Table 2](#tab2){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}). Sensitivity analysis confirmed the pooled results (data not shown).

3.4. Stratified Analysis by Gender {#sec3.4}
----------------------------------

As shown in [Table 2](#tab2){ref-type="table"}, no significant relationship of prediagnostic IgE levels (total IgE level and respiratory allergen-specific IgE level) with the risk of overall brain tumors was demonstrated among either men or women. Additionally, the role of prediagnostic IgE levels in glioma development did not change by gender, as suggested by stratified analysis by type of brain tumors in men and women, respectively ([Table 2](#tab2){ref-type="table"}).

3.5. Heterogeneity Analysis and Publication Bias Risk {#sec3.5}
-----------------------------------------------------

Results of Cochran\'s *Q*-statistic test and *I* ^2^ test were presented in [Table 2](#tab2){ref-type="table"} detailedly. There was no between-study heterogeneity no matter in overall analysis or stratified analyses by type of brain tumors and gender ([Table 2](#tab2){ref-type="table"}). Begg\'s funnel plots and Egger\'s test implicated no potential publication bias in our study (data not shown).

4. Discussion {#sec4}
=============

Common allergies consist of eczema, hay fever, and allergic asthma mediated by hypersensitivity reactions and high serum IgE concentrations. However, not all allergic individuals are characteristic of high IgE levels, and increased level of serum IgE cannot reflect all allergic diseases. The modifying effects of prediagnostic IgE levels on diseases initiation and progression alter among different diseases. Epidemiological studies have suggested inverse association between allergic diseases and malignant tumors \[[@B10], [@B24]\]. Self-reported allergies were shown to be associated with reduced risk of pancreatic cancer \[[@B25]\]. Allergy seems to be strongly and inversely related to childhood non-Hodgkin\'s lymphomas, as suggested by a recent pooled analysis \[[@B26]\]. Taken together, hypersensitivity was associated with reduced risk of malignancies, implicating an immune surveillance theory in carcinogenesis. Quite the reverse, there was no epidemiological support for the reverse association between allergic diseases and the risk of breast, prostate, and colorectal cancer \[[@B27]\]. Interestingly, a positive relationship between atopy and prostate cancer, but not breast and colorectal cancers, was demonstrated in that study \[[@B27]\]. Thus, despite extensive research, findings for allergy conditions and tumorigenesis warrant further elucidation.

IgE is a critical atopic marker linking allergy and cancer. Jensen-Jarolim et al. elaborated an evolving new field called AllergoOncology, which gave new insights into the role of IgE-mediated allergy in malignancies \[[@B28]\]. Due to its capacity of destroying tumor cells, IgE antibodies specifically targeting overexpressed tumor antigens have been identified as useful immunological agents. Besides, IgE nonspecifically binding to tumor cells has also been demonstrated to be a powerful adjuvant establishing tumor-specific immune memory \[[@B29], [@B30]\]. Moreover, IgE antibodies not only play critical roles in natural tumor surveillance, but also participate in active and adaptive immune responses involved in antitumor immunotherapy \[[@B28]\]. Additionally, macrophages, mast cells, and other IgE-receptor-expressed immune cells can become potent effectors in antitumor immunity; that is antitumor immunity by the bridge IgE. A number of epidemiological studies have been performed to estimate the association between prediagnostic IgE levels and brain tumors risk \[[@B17]--[@B23]\]. Nevertheless, the findings were inconsistent and inconclusive. Calboli et al. reported that total IgE levels were inversely associated with glioma risk \[[@B18]\]. However, no such association was observed for either respiratory allergen-specific or food allergen-specific IgE levels \[[@B18]\]. On the contrary, individuals with high levels of respiratory allergen-specific IgE were at decreased risk of glioma, but not meningioma \[[@B19]\]. As suggested by the study by Wiemels et al., increased serum total IgE concentrations were negatively related to the development of meningioma, indicating a protective role of atopic marker IgE in meningioma risk \[[@B23]\]. Taken together, the modifying effect of serum IgE level on brain tumors risk appears different with diverse types of brain cancer and the source of determined IgE. Up till now, no meta-analysis has been conducted to precisely estimate roles of prediagnostic IgE levels (total IgE level and/or allergen-specific IgE level) in brain tumorigenesis. A recent meta-analysis supported the evidence that allergic conditions were negatively related to the risk of glioma, suggesting a protective role of allergy in glioma development \[[@B31]\]. Nonetheless, the authors failed to assess the influence of specific allergies such as hay fever, eczema as well as allergic asthma, and allergic biomarker IgE in brain cancer risk. The association between different source of serum IgE and brain tumors risk, meningioma in particular, remains obscure and warrants further investigation. Our study firstly showed that increased level of total prediagnostic IgE but not respiratory allergen-specific IgE played a protective role in the risk of brain tumors, particularly glioma. It must be mentioned that the relationship of meningioma risk with prediagnostic IgE levels needs to be elucidated by more relevant epidemiological studies.

SNPs are supported to be important risk factors in brain tumorigenesis \[[@B5], [@B6], [@B32]\]. They can confer modifying effects on brain tumors risk independently or in combination with other factors, for instance, smoking and ionizing radiation. Interestingly, allergy-related SNPs can influence the development of brain tumors by interacting with immunological factors like prediagnostic IgE levels, which implicates critical roles of immune susceptibility factors in the etiology of brain cancers \[[@B32]\]. Gene polymorphisms of IL-4, IL-4R, and IL-13 represent promising immune factors in regulating IgE levels and tumorigenesis \[[@B32]--[@B34]\]. Unfortunately, we failed to investigate roles of such allergy-related SNPs in brain cancer risk in combination with prediagnostic IgE levels, in that very few studies have elucidated this issue up to date. The interaction between SNPs and serum IgE levels warrants further investigation to provide more support for the link between allergies and risk of brain tumors.

Findings in our study should be interpreted cautiously because of some limitations. Firstly, the strength of our study especially in relation to the meningioma risk was insufficient due to limited eligible studies published to date. Besides, only studies clearly presenting information about the detection of prediagnostic IgE levels were included into our study. More relevant studies with enough statistical power are encouraged in the future. Secondly, IgE levels were significantly associated with gender, age, smoking status, and ethnicity in glioma risk \[[@B21]\]. Apart from gender and type of brain tumors, we did not perform other stratified analyses by smoking, age, and so on, for lack of available published data. More studies with high quality are warranted for more precise estimates. Thirdly, inverse association was identified between elevated respiratory allergen-specific IgE level and high-grade glioma risk rather than low-grade glioma \[[@B19]\]. The effect of prediagnostic IgE levels on different subtypes of glioma was not estimated due to insufficient included publications. Lastly, the pooled analysis was based on unadjusted estimates, which might introduce bias. Some confounding factors including age, sex, IgE detection methods, smoking status, and education level of subjects should be considered in future studies.

5. Conclusions {#sec5}
==============

A significant inverse association between total IgE levels and brain tumors risk is suggested in the present meta-analysis. The measurement of allergic biomarker IgE is valuable in targeting brain tumors, particularly glioma. In addition, the association between prediagnostic IgE levels and meningioma risk warrants further investigation. The study implicates that IgE monoclonal antibodies directing specifically against tumor-associated antigens can be a promising way of passive immunotherapy in brain cancer treatment.
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###### 

Characteristics of all studies.

  Study                            Year   Brain tumors   Origins   Number of cases   Number of controls   Baseline time   Matching factors
  -------------------------------- ------ -------------- --------- ----------------- -------------------- --------------- ----------------------------------------------------------------------------------------------------------------------
  Amirian et al. \[[@B17]\]        2013   Glioma         USA       362               462                  2001--2006      Age, sex, and frequency
  Schwartzbaum et al. \[[@B20]\]   2012   Glioma         Norway    594               1177                 1974--2007      Date of blood collection, 2-year age interval at blood collection, and sex
  Schlehofer et al. \[[@B19]\]     2011   Glioma         Europe    275               528                  2002--2005      Study centre, gender, data of birth, age, date of blood collection, time of blood collection, and length of followup
  Schlehofer et al. \[[@B19]\]     2011   Meningioma     Europe    175               343                  2002--2005      Study centre, gender, data of birth, age, date of blood collection, time of blood collection, and length of followup
  Calboli et al. \[[@B18]\]        2011   Glioma         USA       169               520                  1976--2009      Age, age at blood draw, age at diagnosis, and ethnicity
  Wiemels et al. \[[@B23]\]        2011   Meningioma     USA       265               145                  2006--2009      Age, frequency, and state of residence
  Wiemels et al. \[[@B22]\]        2009   Glioma         USA       393               470                  2001--2004      Age, sex, ethnicity, and frequency
  Wiemels et al. \[[@B21]\]        2004   Glioma         USA       228               289                  1997--2000      Age, sex, ethnicity, and frequency

###### 

Summary of meta-analysis results.

  Comparisons                                 Number of studies   ^a^RR \[95% CI\]      ^b^ *P* value   Tests for heterogeneity   
  ------------------------------------------- ------------------- --------------------- --------------- ------------------------- -------
  *Total IgE level*                                                                                                                
  Brain tumors                                6                   0.73 \[0.61--0.86\]   \<0.001         39.5                      0.142
   Men                                        2                   0.83 \[0.63--1.10\]   0.202           0.0                       0.602
   Women                                      2                   0.69 \[0.43--1.11\]   0.125           0.0                       0.450
  Glioma                                      5                   0.74 \[0.62--0.88\]   0.001           50.6                      0.088
   Men                                        2                   0.83 \[0.63--1.10\]   0.202           0.0                       0.602
   Women                                      2                   0.69 \[0.43--1.11\]   0.125           0.0                       0.450
  *Respiratory allergen-specific IgE level*                                                                                        
  Brain tumors                                6                   0.88 \[0.77--1.00\]   0.055           0.0                       0.527
   Men                                        4                   0.96 \[0.78--1.19\]   0.744           0.0                       0.770
   Women                                      4                   0.87 \[0.67--1.15\]   0.331           51.6                      0.103
  Glioma                                      5                   0.87 \[0.76--1.00\]   0.051           0.0                       0.407
   Men                                        3                   0.99 \[0.80--1.23\]   0.923           0.0                       0.878
   Women                                      3                   0.81 \[0.59--1.10\]   0.172           60.3                      0.081

^a^RR: relative risk; 95% CI: 95% confidence interval; ^b^ *P*: *P* values for pooled analysis; ^c^ *P*: *P* values for heterogeneity analysis.

[^1]: Academic Editor: Aurelio Ariza
